NPFCX
Price
$57.50
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
RPEBX
Price
$59.87
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
Ad is loading...

NPFCX vs RPEBX

Header iconNPFCX vs RPEBX Comparison
Open Charts NPFCX vs RPEBXBanner chart's image
American Funds New Perspective C
Price$57.50
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
American Funds New Perspective R2E
Price$59.87
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
NPFCX vs RPEBX Comparison Chart
Loading...
VS
NPFCX vs. RPEBX commentary
Sep 16, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NPFCX is a StrongBuy and RPEBX is a StrongBuy.

FUNDAMENTALS
Fundamentals
NPFCX (142B) and RPEBX (142B) have equal amount of cash in the bank . RPEBX pays higher dividends than NPFCX: RPEBX (0.46) vs NPFCX (0.20). NPFCX was incepted earlier than RPEBX: NPFCX (24 years) vs RPEBX (10 years). NPFCX (17.00) and RPEBX (17.00) have comparable annual turnover. NPFCX (250) and RPEBX (250) have matching initial minimum investment requirements. RPEBX (16.17) and NPFCX (15.64) have marching annual gain over last year. RPEBX return over 5 years is better than : 40.91 vs. NPFCX (38.80).
NPFCXRPEBXNPFCX / RPEBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years10 years-
Gain YTD14.07014.31298%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets142B142B100%
Annual Yield % from dividends0.200.4643%
Returns for 1 year15.6416.1797%
Returns for 3 years-9.02-8.06112%
Returns for 5 years38.8040.9195%
Returns for 10 years59.0062.2395%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INBX16.411.33
+8.82%
Inhibrx Biosciences Inc.
STM28.590.64
+2.29%
STMicroelectronics NV
HLF7.420.13
+1.78%
Herbalife Ltd
TRIP13.510.18
+1.35%
TripAdvisor
CGTX0.60N/A
-0.58%
Cognition Therapeutics